Ingenia Therapeutics

Ingenia Therapeutics (Ticker: 952509 KS) develops treatments intended to repair and protect small blood vessels damaged by disease. Its drug candidates are being studied for retinal diseases, chronic kidney disease, glaucoma, cancer and pulmonary hypertension. Proceeds were intended to advance clinical trials, develop additional drug candidates and expand partnerships with global pharmaceutical and biotechnology companies.

The scheduled listing date on Korea Exchange (KOSDAQ) was August 18, 2026. The proposed offering comprises 5,000,000 shares at an indicative price of KRW 12000 per share. The base offering would represent KRW 60.00 billion, approximately $45.13 million in gross proceeds, excluding any unexercised over-allotment.

Samsung Securities was the sole lead underwriter.